<p>Beck Mack
&amp; Oliver LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份减少了 15.3%。该基金在此期间出售了 3,287 股后，持有该公司 18,191 股股票。根据其最近向证券交易委员会的提交，Beck Mack
&amp; Oliver LLC 在艾伯维的持股价值为 3,811,000 美元。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也对 ABBV 的持仓进行了调整。TD Capital Management LLC 在第一季度将其在艾伯维的持股增加了 82.9%。TD Capital Management LLC 目前拥有 128 股该公司股票，价值 27,000 美元，此前在上个季度又增持了 58 股。Abound Financial LLC 在第一季度以约 30,000 美元的价格购买了艾伯维的新股份。Cypress Capital Management LLC WY 在第一季度以约 35,000 美元的价格购买了艾伯维的新股份。Pinney
&amp; Scofield Inc. 在第四季度以约 36,000 美元的价格购买了艾伯维的新股份。最后，Inlight Wealth Management LLC 在第一季度以约 42,000 美元的价格购买了艾伯维的新股份。目前，70.23% 的股票由机构投资者持有。</p>
<h2>分析师评级上调与下调</h2>
<p>几家券商最近对 ABBV 发表了评论。大和资本市场将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并在 8 月 7 日的报告中设定了 214.00 美元的目标价。法国巴黎银行在 5 月 8 日的报告中将艾伯维的评级上调至 “持有”。大和美国在 8 月 7 日的研究报告中将艾伯维的评级从 “持有” 上调至 “强力买入”。花旗集团在 6 月 11 日的研究报告中将艾伯维的目标价提高至 205.00 美元，并给予该公司 “持有” 评级。最后，派珀桑德勒在 8 月 12 日的研究报告中开始覆盖艾伯维。他们给予了 “增持” 评级，并设定了 231.00 美元的目标价。四位研究分析师对该股票给予了强力买入评级，十六位给予了买入评级，六位给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 214.95 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p><strong>查看我们最新的艾伯维股票报告</strong></p>
<h2>内部人士买卖</h2>
<p>在相关消息中，执行副总裁 Azita Saleki-Gerhardt 于 8 月 12 日星期二出售了 42,370 股股票，交易均价为 198.42 美元，总价值为 8,407,055.40 美元。出售完成后，该执行副总裁直接持有 177,292 股该公司股票，价值约为 35,178,278.64 美元。这代表了其持仓的 19.29% 的减少。该交易已在向 SEC 的提交中披露，相关信息可通过 SEC 网站访问。此外，执行副总裁 Nicholas Donoghoe 于 8 月 5 日星期二出售了 13,295 股股票，交易均价为 198.51 美元，总价值为 2,639,190.45 美元。出售完成后，该执行副总裁直接持有 58,247 股该公司股票，价值为 11,562,611.97 美元。该交易使其持股减少了 18.58%。该出售的披露信息可在此处找到。0.25% 的股票由公司内部人士持有。</p>
<h2>艾伯维价格表现</h2>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>艾伯维（NYSE:ABBV）股票在星期五开盘价为 210.25 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务与股本比率为 44.14。艾伯维公司的 12 个月低点为 163.81 美元，12 个月高点为 218.66 美元。该股票的 50 日移动平均线为 195.05 美元，200 日移动平均线为 193.54 美元。该公司的市值为 3714.2 亿美元，市盈率为 100.12，PEG 比率为 1.35，贝塔值为 0.50。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日星期四发布了其财报。该公司报告本季度每股收益为 2.97 美元，低于分析师一致预期的 3.24 美元，差额为 0.27 美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司本季度的收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。去年同期，该公司每股收益为 2.65 美元。与去年同期相比，艾伯维本季度的收入增长了 6.6%。卖方分析师预测，艾伯维公司本财年将发布 12.31 的每股收益。</p>
<h2>艾伯维宣布分红</h2>
<p>该公司最近还宣布了季度分红，于 8 月 15 日星期五支付。7 月 15 日的股东获得了每股 1.64 美元的分红。这相当于年化 6.56 美元的分红和 3.1% 的分红收益率。该分红的除息日为 7 月 15 日。艾伯维的分红支付比率目前为 312.38%。</p>
<h2>关于艾伯维</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；以及 Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过艾伯维</li>
<li>股息支付比率计算器</li>
<li>DICKS 体育用品公司的股票在财报后下跌——值得买吗？</li>
<li>如何捕捉股息增长的好处</li>
<li>AI 引擎：康明斯意外的增长动力</li>
<li>投资旅游股票的好处</li>
<li>小型工业公司看到激增的增长：原因在这里</li>
</ul>
<p><strong>想看看其他对 ABBV 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Beck Mack & Oliver LLC 在第一季度减少了对艾伯维（AbbVie Inc.，纽约证券交易所代码：ABBV）15.3% 的持股，出售了 3,287 股，剩余 18,191 股，市值为 381 万美元。其他机构投资者也调整了他们的持仓，TD Capital Management 增加了 82.9% 的持股。分析师对艾伯维的评级有所改善，多次上调评级，普遍评级为 “适度买入”。艾伯维的股票开盘价为 210.25 美元，市值为 3,714.2 亿美元，最近的财报显示每股收益为 2.97 美元，低于预期</p>

<p>Beck Mack &amp; Oliver LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 15.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,191 shares of the company's stock after selling 3,287 shares during the period. Beck Mack &amp; Oliver LLC's holdings in AbbVie were worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Beck Mack
&amp; Oliver LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份减少了 15.3%。该基金在此期间出售了 3,287 股后，持有该公司 18,191 股股票。根据其最近向证券交易委员会的提交，Beck Mack
&amp; Oliver LLC 在艾伯维的持股价值为 3,811,000 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in ABBV. TD Capital Management LLC boosted its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares during the last quarter. Abound Financial LLC bought a new stake in AbbVie in the first quarter valued at approximately $30,000. Cypress Capital Management LLC WY bought a new stake in AbbVie in the first quarter valued at approximately $35,000. Pinney &amp; Scofield Inc. bought a new stake in AbbVie in the fourth quarter valued at approximately $36,000. Finally, Inlight Wealth Management LLC bought a new stake in AbbVie in the first quarter valued at approximately $42,000. 70.23% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也对 ABBV 的持仓进行了调整。TD Capital Management LLC 在第一季度将其在艾伯维的持股增加了 82.9%。TD Capital Management LLC 目前拥有 128 股该公司股票，价值 27,000 美元，此前在上个季度又增持了 58 股。Abound Financial LLC 在第一季度以约 30,000 美元的价格购买了艾伯维的新股份。Cypress Capital Management LLC WY 在第一季度以约 35,000 美元的价格购买了艾伯维的新股份。Pinney
&amp; Scofield Inc. 在第四季度以约 36,000 美元的价格购买了艾伯维的新股份。最后，Inlight Wealth Management LLC 在第一季度以约 42,000 美元的价格购买了艾伯维的新股份。目前，70.23% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several brokerages recently commented on ABBV. Daiwa Capital Markets upgraded AbbVie from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $214.00 target price on the stock in a report on Thursday, August 7th. BNP Paribas upgraded AbbVie to a &#34;hold&#34; rating in a report on Thursday, May 8th. Daiwa America raised AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, August 7th. Citigroup boosted their price target on AbbVie to $205.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, June 11th. Finally, Piper Sandler initiated coverage on AbbVie in a research note on Tuesday, August 12th. They issued an &#34;overweight&#34; rating and a $231.00 price target on the stock. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $214.95.</p>
<div class="lb-trans"><p>几家券商最近对 ABBV 发表了评论。大和资本市场将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并在 8 月 7 日的报告中设定了 214.00 美元的目标价。法国巴黎银行在 5 月 8 日的报告中将艾伯维的评级上调至 “持有”。大和美国在 8 月 7 日的研究报告中将艾伯维的评级从 “持有” 上调至 “强力买入”。花旗集团在 6 月 11 日的研究报告中将艾伯维的目标价提高至 205.00 美元，并给予该公司 “持有” 评级。最后，派珀桑德勒在 8 月 12 日的研究报告中开始覆盖艾伯维。他们给予了 “增持” 评级，并设定了 231.00 美元的目标价。四位研究分析师对该股票给予了强力买入评级，十六位给予了买入评级，六位给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 214.95 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的艾伯维股票报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Azita Saleki-Gerhardt 于 8 月 12 日星期二出售了 42,370 股股票，交易均价为 198.42 美元，总价值为 8,407,055.40 美元。出售完成后，该执行副总裁直接持有 177,292 股该公司股票，价值约为 35,178,278.64 美元。这代表了其持仓的 19.29% 的减少。该交易已在向 SEC 的提交中披露，相关信息可通过 SEC 网站访问。此外，执行副总裁 Nicholas Donoghoe 于 8 月 5 日星期二出售了 13,295 股股票，交易均价为 198.51 美元，总价值为 2,639,190.45 美元。出售完成后，该执行副总裁直接持有 58,247 股该公司股票，价值为 11,562,611.97 美元。该交易使其持股减少了 18.58%。该出售的披露信息可在此处找到。0.25% 的股票由公司内部人士持有。</p>
</div><h2>AbbVie Price Performance</h2>
<div class="lb-trans"><h2>艾伯维价格表现</h2>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>Shares of NYSE:ABBV opened at $210.25 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $218.66. The stock's 50 day moving average is $195.05 and its 200-day moving average is $193.54. The firm has a market capitalization of $371.42 billion, a price-to-earnings ratio of 100.12, a PEG ratio of 1.35 and a beta of 0.50.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV）股票在星期五开盘价为 210.25 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务与股本比率为 44.14。艾伯维公司的 12 个月低点为 163.81 美元，12 个月高点为 218.66 美元。该股票的 50 日移动平均线为 195.05 美元，200 日移动平均线为 193.54 美元。该公司的市值为 3714.2 亿美元，市盈率为 100.12，PEG 比率为 1.35，贝塔值为 0.50。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. During the same period in the previous year, the company earned $2.65 earnings per share. AbbVie's revenue for the quarter was up 6.6% compared to the same quarter last year. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日星期四发布了其财报。该公司报告本季度每股收益为 2.97 美元，低于分析师一致预期的 3.24 美元，差额为 0.27 美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司本季度的收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。去年同期，该公司每股收益为 2.65 美元。与去年同期相比，艾伯维本季度的收入增长了 6.6%。卖方分析师预测，艾伯维公司本财年将发布 12.31 的每股收益。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend was Tuesday, July 15th. AbbVie's dividend payout ratio is presently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，于 8 月 15 日星期五支付。7 月 15 日的股东获得了每股 1.64 美元的分红。这相当于年化 6.56 美元的分红和 3.1% 的分红收益率。该分红的除息日为 7 月 15 日。艾伯维的分红支付比率目前为 312.38%。</p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于艾伯维</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；以及 Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Dividend Payout Ratio Calculator</li>
<li>DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Engines to AI: Cummins’ Surprising Growth Driver</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Smaller Industrials Names Seeing Surging Growth: Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过艾伯维</li>
<li>股息支付比率计算器</li>
<li>DICKS 体育用品公司的股票在财报后下跌——值得买吗？</li>
<li>如何捕捉股息增长的好处</li>
<li>AI 引擎：康明斯意外的增长动力</li>
<li>投资旅游股票的好处</li>
<li>小型工业公司看到激增的增长：原因在这里</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ABBV 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com 获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Beck Mack & Oliver LLC 出售了 3,287 股艾伯维公司（AbbVie Inc.）的股票，股票代码为$ABBV